Atomo Diagnostics Ltd (ASX: AT1) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Atomo Diagnostics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$19.82 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
639.20 million
Earnings per share
-0.012
Dividend per share
N/A
Year To Date Return
36.36%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Atomo Diagnostics Ltd (ASX: AT1)
Latest News
Share Gainers
Guess which ASX pharmaceutical stock just rocketed 122%!
Healthcare Shares
3 ASX healthcare shares rocketing 20% to 100% today
Earnings Results
3 ASX healthcare shares punished following full-year results
Earnings Results
Negative result: Atomo Diagnostics (ASX: AT1) shares plunge 18% on half-year earnings
Coronavirus News
Why are ASX COVID test shares climbing today?
Healthcare Shares
Here's why the Atomo (ASX:AT1) share price is rocketing 17% today
Healthcare Shares
Why has the Atomo Diagnostics (ASX: AT1) share price surged 50% since Christmas?
Healthcare Shares
Why is the Atomo Diagnostics (ASX:AT1) share price wobbling on Thursday?
Healthcare Shares
Is AM Diagnostics listed on the ASX?
Share Fallers
Why Afterpay, Atomo, Opthea, & Sealink shares are falling today
Share Market News
Here's why the Atomo (ASX:AT1) share price is crashing 9% today
Healthcare Shares
Why is the Atomo Diagnostics (ASX:AT1) share price halted?
AT1 ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Atomo Diagnostics Ltd
Atomo Diagnostics Limited is a medical device company. Its Rapid Diagnostic Test devices are used both by healthcare professionals and by consumers to screen for a range of diseases and medical conditions
AT1 Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 18 Apr 2024 | $0.03 | $0.00 | 0.00% | 459,880 | $0.03 | $0.03 | $0.03 |
| 17 Apr 2024 | $0.03 | $0.00 | 0.00% | 237,566 | $0.03 | $0.03 | $0.03 |
| 16 Apr 2024 | $0.03 | $0.00 | 0.00% | 607,219 | $0.03 | $0.03 | $0.03 |
| 15 Apr 2024 | $0.03 | $0.00 | 0.00% | 7,471,673 | $0.03 | $0.04 | $0.03 |
| 12 Apr 2024 | $0.03 | $0.00 | 0.00% | 188,654 | $0.03 | $0.03 | $0.03 |
| 11 Apr 2024 | $0.03 | $0.00 | 0.00% | 100,000 | $0.03 | $0.03 | $0.03 |
| 10 Apr 2024 | $0.03 | $0.00 | 0.00% | 978,435 | $0.03 | $0.03 | $0.03 |
| 09 Apr 2024 | $0.03 | $0.00 | 0.00% | 312,281 | $0.03 | $0.03 | $0.03 |
| 08 Apr 2024 | $0.03 | $0.00 | 0.00% | 246,333 | $0.03 | $0.03 | $0.03 |
| 05 Apr 2024 | $0.03 | $0.00 | 0.00% | 931,948 | $0.03 | $0.03 | $0.03 |
| 04 Apr 2024 | $0.03 | $0.00 | 0.00% | 349,488 | $0.03 | $0.03 | $0.03 |
| 03 Apr 2024 | $0.03 | $0.00 | 0.00% | 508,283 | $0.03 | $0.03 | $0.03 |
| 02 Apr 2024 | $0.03 | $0.00 | 0.00% | 134,126 | $0.03 | $0.03 | $0.03 |
| 28 Mar 2024 | $0.03 | $0.00 | 0.00% | 464,744 | $0.03 | $0.03 | $0.03 |
| 27 Mar 2024 | $0.03 | $0.00 | 0.00% | 110,492 | $0.03 | $0.03 | $0.03 |
| 26 Mar 2024 | $0.03 | $0.00 | 0.00% | 205,063 | $0.03 | $0.03 | $0.03 |
| 25 Mar 2024 | $0.03 | $0.00 | 0.00% | 425,316 | $0.03 | $0.03 | $0.03 |
| 22 Mar 2024 | $0.03 | $0.00 | 0.00% | 224,359 | $0.03 | $0.03 | $0.03 |
| 21 Mar 2024 | $0.03 | $0.00 | 0.00% | 760,341 | $0.03 | $0.03 | $0.03 |
| 20 Mar 2024 | $0.03 | $0.00 | 0.00% | 351,812 | $0.03 | $0.03 | $0.03 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 03 Aug 2023 | John Kelly | Expiry | 666,666 | $19,999 |
Options expired.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Paul Alexander Kasian | Non-Executive Director |
Dr Kasian is an executive director with demonstrated achievement in both domestic and international companies encompassing senior leadership, strategy, investment and risk roles. His other roles have included Chief Investment Officer and Head of Global Financials at HSBC Asset Management, Founding Director of Accordius and Founding Director of Wallara Asset Management. He is also Chair of Risk Committee.
|
|
| Mr John Perry Keith | Non-Executive ChairmanNon-Executive Director | Dec 2011 |
Mr Keith is one of the Managing Directors at BNP Paribas, establishing and leading its financial institutions coverage team. Prior to joining BNP Paribas in 2011, Mr Keith held country management and senior business and coverage positions for Nomura Securities in Sydney and Hong Kong. His career comprises working with supranational, sovereign, and institutional clients across all areas of investment and institutional banking. He is Member of the Risk Committee.
|
| Mr John Michael Kelly | FounderChief Executive OfficerManaging Director | Apr 2010 |
Mr Kelly has focused on developing and commercializing innovative healthcare products that enhance usability and performance, having started with CR Bard in Europe developing Class III implantable cardiology products. Prior to joining Unilife in 2005, Mr Kelly spent five years at ResMed where he led the New Product Implementation Group and managed the development of the Mirage Swift and Activa mask systems.
|
| Ms Deborah Neff | Non-Executive Director | Sep 2021 |
Ms Neff has spent most of her career building global businesses. As principal of DJN Consulting, LLC based in the San Francisco Bay Area, Deborah currently works with several privately held healthcare start-up companies providing strategic business advice and mentoring to the executive management teams. Previously was CEO of Evanostics, LLC, Pathwork Diagnostics Inc, and COO at Complete Genomics following a 15-year career with Becton Dickinson, where she last served as President of BD Biosciences, a global business unit of the company. She is an Executive Trustee of the University of California, Davis Foundation and chairs the College of Biological Sciences Leadership Council at the University. He is also member of the Risk Committee.
|
| Dr Cheri Louise Walker | Non-Executive Director | Nov 2022 |
Dr Walker is an executive with more than twenty-five years of experience working with life science and diagnostic companies. Dr. Walker is currently the President, Chief Executive Officer, and Director of Rhinostics. She has previously held senior executive positions at Abcam; Charles River Labs; Qiagen, and Life Technologies, now part of ThermoFisher.
|
| Ms Sally McDow | Company Secretary | Mar 2024 |
-
|
| William Souter | Chief Financial Officer |
-
|
|
| Chandra Sukumar | Chief Operating Officer |
-
|
|
| Sally McDow | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| GZ Family Holdings Pty Ltd | 79,787,536 | 13.98% |
| Dalraida Holdings Pty Limited | 65,120,000 | 11.41% |
| Global Health Investment Fund | 64,811,280 | 11.35% |
| Mr Xiaoyi Lin | 11,500,000 | 2.01% |
| Grand Challenges Canada | 11,390,824 | 2.00% |
| Liverbird Pty Ltd | 10,931,653 | 1.91% |
| ID&E Pty Ltd | 9,032,248 | 1.58% |
| Australia North Holdings Pty | 8,100,000 | 1.42% |
| Mark Andrew Smith | 7,790,224 | 1.36% |
| Mr Ian Fredrick Johnson | 7,506,080 | 1.31% |
| John Michael Kelly | 7,370,248 | 1.29% |
| Leo James Lynch | 7,321,121 | 1.28% |
| Ruth Karen Devney | 5,626,408 | 0.99% |
| Australia West Holdings Pty Ltd | 5,250,000 | 0.92% |
| Sokolov Pty Ltd | 4,031,888 | 0.71% |
| Rue Des Rocs Pty Ltd | 3,800,000 | 0.67% |
| H & L Management Pty Ltd | 3,700,000 | 0.65% |
| Citicorp Nominees Pty Limited | 3,684,031 | 0.65% |
| BNP PARIBAS NOMINEES PTY LTD | 3,399,373 | 0.60% |
| Miss Lisa Marie Mackenzie | 3,351,968 | 0.59% |
